



Crescendo Biologics Announces Prestigious Academic Research Collaborations

Cambridge, UK, 31 May 2019 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces a number of ongoing research partnerships with prestigious academic institutions in the US and Europe. These include:

- The University of Michigan, evaluating pharmacokinetics and pharmacodynamics of Humabodies in tumours;
- Navarrabiomed Biomedical Research Centre in Spain, evaluating the impact of novel targeted Humabody® blockade on T-cell checkpoint signalling pathways; and
- The University of North Carolina at Chapel Hill, exploring Humabody®-based CAR-T formats

Crescendo is breaking new ground in generating Humabody therapeutics formatted for optimal target engagement. Working with world-leading academic groups such as these will serve to accelerate Crescendo's ability to bring these novel molecules into the clinic.

Theodora Harold, CEO of Crescendo, commented:

"We are pleased to announce three of our ongoing academic collaborations with prestigious research institutions in the US and Europe. These universities are at the forefront of their fields and their cutting edge research will be able to showcase the benefits of our novel T-cell enhancing pipeline. Working with these institutions is excellent validation of Crescendo's ability to generate highly novel therapeutic formats and we look forward to the research being published."

-Ends-

For more information, please contact:

Crescendo Biologics

Theodora Harold, CEO

+ 44 (0)1223 497140

info@crescendobiologics.com

Instinctif Partners

Melanie Toyne-Sewell, Dr Christelle Kerouedan, Deborah Bell

+ 44 (0)20 7457 2020

crescendo@instinctif.com



Notes to Editors

About Crescendo Biologics Ltd

Crescendo Biologics is a T-cell enhancing company. Crescendo develops potent, truly differentiated Humabody® therapeutics with a focus on innovative, targeted T-cell approaches in oncology.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel CD137-PSMA bispecific for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment – avoiding systemic toxicity.

The Company's ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® V_H). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website: www.crescendobiologics.com.